Genentech-ImmunoGen breast cancer drug wins FDA approval

02/24/2013 | Reuters · Genetic Engineering & Biotechnology News

Roche Holding unit Genentech and ImmunoGen obtained FDA approval to market Kadcyla, or ado-trastuzumab emtansine, as a treatment for patients who have HER2-positive, metastatic breast cancer who don't respond to other treatments. Because of associated mortality, liver and heart risks, the drug will carry a boxed warning. The approval means a $10.5 million milestone fee will be paid to ImmunoGen.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ